EUFLEXXA (1% SODIUM HYALURONATE)
Ferring Pharmaceuticals, Inc. · Decision date Dec 3, 2004
What did the FDA approve?
FDA approved PMA P010029 on December 3, 2004, for EUFLEXXA (1% sodium hyaluronate), submitted by Ferring Pharmaceuticals, Inc. The device is classified under product code MOZ as hyaluronic acid for intraarticular use in the orthopedic specialty. The approval statement identifies the indication as treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics such as acetaminophen.
The record contains no supplement type or supplement reason, so this entry reflects the original PMA decision rather than a change to a previously approved system. The source statement reports the intended purpose but does not provide independent proof of safety or clinical effectiveness. No clinical trial data, comparative efficacy findings, or post-approval requirements appear in the supplied fields.
FDA approval order statement
APPROVAL FOR NUFLEXXA (1% SODIUM HYALURONATE). THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Dec 3, 2004
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010029
- Regulatory pathway
- Premarket approval application
- Applicant
- Ferring Pharmaceuticals, Inc.
- Product code
- MOZ
- Decision code
- APPR
- Decision date
- Dec 3, 2004
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Acid, hyaluronic, intraarticular.
- Applicant
- Ferring Pharmaceuticals, Inc.
- Product code
- MOZ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P010029 received
Application receipt date recorded by FDA.
P010029 · FDA decision
APPR
P010029/S042 · Related supplement
EUFLEXXA (1% SODIUM HYALURONATE)
P010029/S043 · Related supplement
EUFLEXXA (1% sodium hyaluronate)
Timeline entries are records held by MedtechLedger for P010029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EUFLEXXA (1% SODIUM HYALURONATE)P010029/S042 | Ferring Pharmaceuticals, Inc. | PMA supplement | Oct 16, 2025 | FDA |
EUFLEXXA (1% sodium hyaluronate)P010029/S043 | Ferring Pharmaceuticals, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Explore the linked device profile
Other records with product code MOZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Gel-OneP080020/S056 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
SUPARTZ FXP980044/S067 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
Orthovisc Injectable Intra-Articular DevicesP030019/S028 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
GEL-ONEP080020/S057 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
SUPARTZ FXP980044/S068 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ferring Pharmaceuticals, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Interpace Pkwy., Parsippany, NJ, 07054
Sources and methodology
- Original FDA record: P010029
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



